Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight

Abstract Purpose An increase of IGF-1 has been reported during therapy with dopamine agonists (DA) for prolactinomas; in such cases a correct diagnosis is pivotal to avoid an unnecessary reduction or withdrawal of DA, which are needed to maintain normal prolactin levels. This study was aimed to meas...

詳細記述

書誌詳細

主要な著者:	S. Caprio, T. Pilli, S. Cantara, F. Sestini, C. Fioravanti, C. Ciuoli, C. Dalmiglio, A. Corbo, M. G. Castagna
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2024-06-01
シリーズ:	BMC Endocrine Disorders
主題:	Prolactinoma Dopamine-agonists IGF-1 Body mass index
オンライン･アクセス:	https://doi.org/10.1186/s12902-024-01622-4
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!